•
Jul 31, 2024

HealthEquity Q2 2025 Earnings Report

HealthEquity's Q2 2025 financial results were released, showcasing revenue growth and increased profitability.

Key Takeaways

HealthEquity reported strong second-quarter results, with a 23% increase in revenue to $299.9 million and a significant rise in net income to $35.8 million. The company also announced a $300 million stock repurchase program.

Revenue increased by 23% year-over-year, reaching $299.9 million.

Net income rose to $35.8 million, a substantial increase from $10.6 million in the same quarter last year.

Non-GAAP net income increased by 67% to $76.3 million.

The company reported 9.4 million HSAs, a 15% increase compared to the previous year.

Total Revenue
$300M
Previous year: $244M
+23.1%
EPS
$0.86
Previous year: $0.53
+62.3%
Total HSAs
9.4M
Previous year: 8.2M
+14.6%
HSAs with investments
711K
Previous year: 574K
+23.9%
Total Accounts
16.3M
Previous year: 15M
+8.7%
Gross Profit
$173M
Previous year: $151M
+14.7%
Cash and Equivalents
$327M
Previous year: $290M
+12.6%
Free Cash Flow
$107M
Previous year: $76.6M
+40.1%
Total Assets
$3.51B
Previous year: $3.07B
+14.6%

HealthEquity

HealthEquity

HealthEquity Revenue by Segment

Forward Guidance

For the fiscal year ending January 31, 2025, HealthEquity expects revenue between $1.165 billion and $1.185 billion, net income between $94 million and $109 million, and Adjusted EBITDA between $458 million and $478 million.

Positive Outlook

  • Revenue is expected to be between $1.165 billion and $1.185 billion.
  • Net income is projected to be between $94 million and $109 million.
  • Net income per diluted share is expected to be between $1.05 and $1.22.
  • Non-GAAP net income is forecasted to be between $265 million and $280 million.
  • Adjusted EBITDA is anticipated to be between $458 million and $478 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income